Nina has often stated that Dimerix is fully funded for the phase 3 trials and that more deals are in the pipeline prior to phase 3 completion. There is confidence in the science in the existing agreements. And researching the science and scientists involved - it further enhances that confidence. DMX-200 (repagermanium), reduces the amount of proteinuria (when protein from your blood collects in your urine) and slows the decline of kidney function, when taken in addition to a medicine called an angiotensin II receptor blocker (ARB). An ARB is a very commonly used medicine in FSGS.
The above is a recent analysis performed by EUROZ HARTLEYS. It clarifies several points including: 1) The safety and efficacy of DMX 200 i.e.Last month the trial was de-risked when DXB announced DMX-200 had passed the efficacy futility analysis, indicating it is performing better than placebo. Importantly, this analysis represents a patient cohort nearly 10x larger than that of the phase 2 trial. 2) We estimate there is a +A$5 billion total addressable market (TAM) for DMX-200 in the treatment of FSGS. 3) Licensing Deal ⁄ Commercial Validation - DXB executed a major $230m licensing deal last year with European speciality pharma company Advanz Pharma, covering the European Economic Area, and other select regions. The deal could yield up to $220m in milestone payments for DXB, plus royalties of 15-20% on net sales. Additionally, DXB has received multiple non-binding term sheets for global and regional licensing deals, with a USA deal poised to be a major catalyst. 4) Fully Funded - The company is fully funded through to the completion of its phase 3 trial in FSGS with circa $38.6m in pro-forma cash, and an additional $7.7m of options in the money. Moreover, this cash could be supplemented by future licensing deals.
I am accumulating DXB shares - just like I accumulated NEU shares from $1.71 to $18.90 just last week (average $4)....
When you research DXB - it ticks all the boxes. DYOR. Start with Google! GLTAH.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)